Regeneron-JPM 2026 Presentation - FINAL.pdf

1、January 12,2026J.P.MorganHealthcare ConferenceThis non-promotional presentation contains investigational data as well as forward-looking statements;actual results may vary materially.2J.P.Morgan Healthcare ConferenceDr.Leonard Schleifer,MD,PhD Board Co-Chair,Co-Founder,President,&Chief Executive Off

2、icerDr.George Yancopoulos,MD,PhD Board Co-Chair,Co-Founder,President,&Chief Scientific Officer3Note regarding forward-looking statements and non-GAAP financial measuresThis presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future

3、performance of Regeneron Pharmaceuticals,Inc.(Regeneron or the Company),and actual events or results may differ materially from these forward-looking statements.Words such as anticipate,expect,intend,plan,believe,seek,estimate,variations of such words,and similar expressions are intended to identify

4、 such forward-looking statements,although not all forward-looking statements contain these identifying words.These statements concern,and these risks and uncertainties include,among others,competing drugs and product candidates that may be superior to,or more cost effective than,products marketed or

5、 otherwise commercialized by Regeneron and/or its collaborators or licensees(collectively,Regenerons Products)and product candidates being developed by Regeneron and/or its collaborators or licensees(collectively,Regenerons Product Candidates)(including biosimilar versions of Regenerons Products);un

6、certainty of the utilization,market acceptance,and commercial success of Regenerons Products and Regenerons Product Candidates and the impact of studies(whether conducted by Regeneron or others and whether mandated or voluntary)or recommendations and guidelines from governmental authorities and othe